Abivax Files 6-K, Reports Foreign Issuer Status
Ticker: AAVXF · Form: 6-K · Filed: Oct 3, 2024 · CIK: 1956827
| Field | Detail |
|---|---|
| Company | Abivax S.A. (AAVXF) |
| Form Type | 6-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, sec-reporting
TL;DR
Abivax files 6-K, confirms foreign private issuer status, will file 20-F.
AI Summary
Abivax S.A. filed a Form 6-K on October 3, 2024, reporting its status as a foreign private issuer. The company, based in Paris, France, is registered with the SEC under file number 001-41842 and operates in the Pharmaceutical Preparations industry. This filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing confirms Abivax's regulatory status as a foreign private issuer, which impacts its reporting obligations to the SEC.
Risk Assessment
Risk Level: low — This is a routine regulatory filing confirming the company's reporting status and not indicating any new financial or operational developments.
Key Numbers
- 001-41842 — SEC File Number (Identifies Abivax's registration with the SEC.)
Key Players & Entities
- Abivax S.A. (company) — Registrant
- 001-41842 (company) — SEC File Number
- 20241003 (date) — Filing Date
- Paris, France (location) — Company Headquarters
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report Abivax S.A.'s status as a foreign private issuer and to indicate that it files annual reports under Form 20-F.
When was this Form 6-K filed?
This Form 6-K was filed on October 3, 2024.
What is Abivax S.A.'s industry classification?
Abivax S.A. is classified under Pharmaceutical Preparations [2834].
Where is Abivax S.A. headquartered?
Abivax S.A. is headquartered at 7-11 boulevard Haussmann, 75009 Paris, France.
Does Abivax S.A. file annual reports under Form 20-F?
Yes, the filing indicates by check mark that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 189 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-10-03 06:05:07
Filing Documents
- f6k_100324.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-005467.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Abivax SA (Registrant) Date: October 3, 2024 /s/ Marc de Garidel Marc de Garidel Chief Executive Officer